Today submitted its meeting package with the U.S. Food and Drug Administration to discuss advancing KETARX™ into Phase 3 development as a treatment for levodopa-induced dyskinesia in Parkinson’s disease. This Type C meeting allows the Company to discuss with the FDA its plans for a Phase 3 clinical study to support the submission of a new drug application under the 505(b)(2) regulatory pathway for KETARX™ in treating LID-PD. In addition, the Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™. The Type C meeting is via written responses. The goal date for the FDA in providing its written responses is March 20, 2023. PharmaTher Inc shares C.PHRM are trading unchanged at $0.12.